GaLi Pharmaceuticals - B: The small molecule GLP-1 receptor agonist ASC30 demonstrated a 75-day apparent half-life in obese subjects.

Gelei Pharmaceuticals-B announcement, small molecule GLP-1R agonist ASC30 for weight maintenance super long-acting subcutaneous depot formulation in the United States Ib phase clinical study, in obese subjects showed an apparent half-life of 75 days. After a single subcutaneous injection of ASC30 weight maintenance formulation in 8 obese subjects, the time to reach the peak blood concentration of ASC30 was 17 days after administration. Approximately 75 days after administration, ASC30 blood concentration decreased to fifty percent of Cmax value, that is, the apparent half-life is 75 days. Good tolerability supports quarterly dosing. ASC30 is the fastest progressing quarterly intestinal proinsulin drug clinically, and is expected to become a maintenance therapy for long-term weight management.